Purpose: Because the prognostic impact of the clinical and pathological features on cancer-specific survival (CSS) and overall survival (OS) in patients with papillary renal cell carcinoma (papRCC) is still controversial, we want to assess the impact of clinicopathological features, including Fuhrman grade and age, on survival in surgically treated papRCC patients in a large multi-institutional series.
Methods: We established a comprehensive multi-institutional database of surgically treated papRCC patients. Histopathological data collected from 2189 patients with papRCC after radical nephrectomy or nephron-sparing surgery were pooled from 18 centres in Europe and North America. OS and CSS probabilities were estimated using the Kaplan-Meier method. Multivariable competing risks analyses were used to assess the impact of Fuhrman grade (FG1-FG4) and age groups (<50 years, 50-75 years, >75 years) on cancer-specific mortality (CSM).
Results: CSS and OS rates for patients were 89 and 81% at 3 years, 86 and 75% at 5 years and 78 and 41% at 10 years after surgery, respectively. CSM differed significantly between FG 3 (hazard ratio [HR] 4.22, 95% confidence interval [CI] 2.17-8.22; p < 0.001) and FG 4 (HR 8.93, 95% CI 4.25-18.79; p < 0.001) in comparison to FG 1. CSM was significantly worse in patients aged >75 (HR 2.85, 95% CI 2.06-3.95; p < 0.001) compared to <50 years.
Conclusions: FG is a strong prognostic factor for CSS in papRCC patients. In addition, patients older than 75 have worse CSM than patients younger than 50 years. These findings should be considered for clinical decision making.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-017-2078-5 | DOI Listing |
Curr Med Imaging
January 2025
5Department of Radiology, Usak University Teaching and Research Hospital, Usak 64000, Turkey.
Objective: There are variations in prognosis and therapeutic approach for renal cell carcinoma among different histological subtypes. This study aims to determine the relationship between radiologically detected peritumoral neovascularization and the histological subtypes of Renal Cell Carcinoma (RCC) and to assess whether extratumoral neovascularization characteristics detected via imaging can contribute to distinguishing these subtypes alongside tumor size and T-stage.
Materials And Methods: 104 renal tumors from 104 cases consisting of 31 females (29.
Int J Urol
January 2025
Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Background: C-reactive protein (CRP) is a prognostic biomarker for clear cell renal cell carcinoma (ccRCC). However, there may be potential racial heterogeneity in distribution and prognostic impact of CRP level. We investigated potential racial differences in distribution and prognostic impact of preoperative CRP among Asian (AS), African American (AA), and Caucasian (CAUC) patients with non-metastatic ccRCC (nmccRCC).
View Article and Find Full Text PDFSci Rep
January 2025
Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
To investigate the potential association between body mass index (BMI) and the clinicopathological features of patients with clear cell renal cell carcinoma (ccRCC). We retrospectively analyzed data from 2541 patients who underwent partial or radical nephrectomy for renal masses between 2013 and 2023 in a single institution. Patients were divided into normal-weight, overweight, and obese groups based on the Chinese BMI classification.
View Article and Find Full Text PDFCancer Genomics Proteomics
December 2024
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan;
Background/aim: α1-Acid glycoprotein (AGP), also known as orosomucoid, is an acute-phase protein that has been found increased in plasma of cancer patients. This study investigates the role of AGP expression in clear cell renal cell carcinoma (ccRCC) and its association with clinical outcomes.
Materials And Methods: We investigated the correlation between AGP levels and the prognosis of ccRCC through an analysis of The Cancer Genome Atlas (TCGA) database.
Biomark Res
December 2024
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Background: Claudin-3 (CLDN3) participates in the formation of the tight-junctions (TJs) that regulate intercellular permeability. Altered CLDN3 expression has been linked to tumor progression in multiple tumor types. Despite its widespread expression in normal epithelial cells, CLDN3 is considered an attractive drug target candidate, since it may be more accessible in cancer cells than in normal cells due to their less orchestrated cell growth.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!